49
Participants
Start Date
October 8, 2021
Primary Completion Date
September 7, 2022
Study Completion Date
July 31, 2027
Ropeginterferon alfa-2b
Initial dose of 250 µg at Week 0, a medium dose of 350 µg at Week 2, a target dose of 500 µg at Week 4, and a maintenance dose of 500 µg until Week 52.
Peking Union Medical College Hospital, Beijing
Xiangya Hospital Central South University, Changsha
The First Affiliated Hospital of Chongqing Medical Universit, Chongqing
Nanfang Hospital affiliated to Southern Medical University, Guangzhou
Anhui Provincial Hospital, Hefei
Huashan Hospital affiliated to Fudan University, Shanghai
Ruijin Hospital affiliated to Shanghai Jiaotong University, Shanghai
Shenzhen Second People's Hospital, Shenzhen
The First Affiliated Hospital of Soochow University, Suzhou
Institute of Hematology &Blood Diseases Hospital ,Chinese Academy of medical science & Peking Union Medical College, Tianjin
The Second Hospital of Tianjin Medical University, Tianjin
Zhongnan Hospital affiliated to Wuhan University, Wuhan
The First Affiliated Hospital Zhejiang University of Medicine, Zhejiang
Henan Cancer Hospital, Zhengzhou
Lead Sponsor
PharmaEssentia
INDUSTRY